PBT434 prevents the accumulation of glial cell inclusions and insoluble alpha-synuclein in a mouse model of Multiple System Atrophy
Objective: To evaluate PBT434 in a transgenic mouse model of multiple system atrophy (MSA) Background: PBT434 is a novel quinazolinone inhibitor of iron-mediated protein accumulation…Salivary Alpha-Synuclein and tau in Parkinson’s Disease and Progressive Supranuclear Palsy
Objective: The aim of this study is to measure alpha-synuclein (a-syn) total, a-syn oligomers (a-syn olig) and total tau protein concentration in the saliva of…Enhancing protein palmitoylation is protective in alpha-synuclein dependent cytotoxicity
Objective: To determine if enhancement of protein palmitoylation benefits alpha-synuclein (aS) dependent vesicular trafficking defects and cytotoxicity. Background: Recent studies suggest that vesicular trafficking defects…A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson’s disease: Study Design
Objective: To assess the safety and tolerability of nilotinib (150-300 mg QD) in moderate/advanced and early/de novo Parkinson disease (PD) participants. Background: Studies in cell…Possible neurotoxic hazards of common adulterants in Tea among Drosophila; ascertainment of toxicity of Tea preparations from local shops of an Indian city
Objective: The present study assesses the neurotoxic implications of common adulterants of Tea in drosophila system in terms of tremor behaviour and neurochemical changes. Also…Bidirectional gut-to-brain and brain-to-gut propagation of α-synuclein pathology in non-human primates
Objective: The prototypic synucleinopathy Parkinson's disease (PD) is hypothesized to spread out from the enteric nervous system (i.e. the gut) via the vagal nerve up…Automated immunohistochemical detection of pathological alpha-synuclein in human tissue biopsy
Objective: The goals of this study were to create a highly sensitive brightfield immunohistochemical (IHC) assay for pathological alpha-synuclein (aSyn) in formalin-fixed, paraffin embedded (FFPE)…A Study to Evaluate the Efficacy of PRX002/RG7935 in Participants With Early Parkinson’s Disease (PASADENA) – Study Design
Objective: To evaluate the efficacy of the anti-alpha-synuclein monoclonal antibody PRX002/RG7935 in a proof-of-concept Phase 2 study in patients with early Parkinson’s disease (PD). Background:…A promising model for cognitive dysfunction in Parkinson’s Disease by AAV-mediated alpha-synuclein overexpression in hippocampus
Objective: Our aim is to model cognitive dysfunction of Parkinson's disease (PD) together with motor deficits by targeted overexpression of alpha-synuclein (a-syn) in bilateral dentate…Presence of Lewy dots in the brain of patients with Creutzfeldt-Jakob disease
Objective: We have investigated whether alpha-synuclein deposits exists in the brain of patients with Creutzfelt-Jakob disease Background: Creutzfeldt-Jakob’s disease (CJD) is a prion neurodegenerative disorder…
- « Previous Page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- …
- 60
- Next Page »